The phase 1 clinical trial is a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal ...

Regenxbio's rolling BLA submission completion of RGX-121 for the treatment of patients with MPS II expected in Q1 of 2025.

US-based biotechnology company Ocugen has dosed the first subject in a multicentre Phase I trial of OCU200 for diabetic ...

Mississauga, Ontario Tuesday, January 21, 2025, 14:00 Hrs [IST] ...

On completion of the scans and tests, he said: “You have early age-related macular degeneration.” When he saw my face fall, he added: “AMD – it’s very common.” My grandmother suffered.

Vabysmo Product Monograph, December 13, 2024. 2. Song P, et al. Global epidemiology of retinal vein occlusion: a systematic review and meta-analysis of prevalence, ...

Shares of Outlook Therapeutics jumped after the company said it continues to progress the development of its treatment for wet age-related macular degeneration, which causes blurred or reduced ...

Outlook Therapeutics, Inc. has announced a key development in the treatment of wet age-related macular degeneration (wet AMD) with the National Institute for Health and Care Excellence (NICE ...

Outlook (OTLK) stock fell 10% after the company said it had completed a study analysis for its drug ONS-5010 and entered into ...

A multidisciplinary team of researchers from the Istituto Italiano di Tecnologia (IIT-Italian Institute of Technology) and ...

Age-related macular degeneration (AMD ... 30% of cases progress to the more severe vision loss associated with wet AMD within 10 years (1 Trusted Source Massively Parallel Screening ...